Fairvalue-Calculator Fairvalue-Calculator
EN DE

TFBS Bioscience Inc (6939) Fair Value & Analysis

Healthcare · TW · Market cap 700M TWD

Price19.90 TWD
Fair Value99.73 TWD
Upside+401.2%
Quality95/100
Evidence: Low Range 74.79 TWD – 124.66 TWD

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

TFBS Bioscience Inc (6939) currently trades at 19.90 TWD, while our model-based Fair Value estimate is 99.73 TWD — implying the stock looks roughly 401.2% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

TFBS Bioscience Inc., a contract research organization, provides biological testing services in Taiwan. It offers viral vector manufacturing services for cell and gene therapy products; and biosafety testing and product release testing for cell and gene therapy products, vaccines, and biologic products. The company was incorporated in 2016 and is headquartered in New Taipei City, Taiwan.

Open the full interactive analysis →

Similar stocks

Thermo Fisher Scientific Inc (TMO) -56% Danaher Corporation (DHR) -37% WuXi AppTec Co (WUXAY) +35% IDEXX Laboratories, Inc (IDXX) -53% Lonza Group (LZAGY) -74% Agilent Technologies, Inc (A) -50%

Frequently asked questions

Is TFBS Bioscience Inc (6939) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 99.73 TWD versus a price of 19.90 TWD — about +401% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 6939?
Our 21-model fair value for TFBS Bioscience Inc is 99.73 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 19.90 TWD.
What is the quality score of 6939?
TFBS Bioscience Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.